German firm Miltenyi Biotec, will launch operations in India with its first office and invest in setting up the Miltenyi Innovation and Technology Center as a Cell and Gene Therapy (CGT) Center of Excellence in Hyderabad. The company aims to enable local development and manufacturing in India to drive affordable and accessible CGT therapies by academia and industry for Indian and global patients.
Miltenyi Biotec’s MACS Prodigy platform is a cornerstone in autologous cell therapy, facilitating end-to-end processing of patient cells, from sample collection to final cell product delivery. The platform supports over 250 different cell types and protocols developed in collaboration with physicians, researchers, biotech companies, and the pharmaceutical industry.
The company’s strategy is to foster collaborations and partnerships with research institutions and biotech companies. Globally, they have partnered with leading biotech and pharma companies such as Novartis, J&J, and British Menopause Society for delivering cell-based products. In India, they are open to forming partnerships and collaborations with biopharmaceutical companies, hospitals, and other institutions to share their expertise and experience in providing cell and gene therapy.
Over 10,000 patients are treated annually with cell products using Miltenyi Biotec’s technologies, and more than 950 investigational new drug (IND) applications, and investigational device exemptions (IDE) with the U.S. Food and Drug Administration are using their technologies and platforms.
Cell and gene therapy are cutting-edge medical treatment technologies designed to address complex diseases such as cancer and immunodeficiency disorders. Miltenyi Biotec collaborates with various stakeholders, including physicians, researchers, and biotech startups, through workshops, training modules, and alliances with academia, to foster innovation and streamline the transition from preclinical to clinical stages.
Miltenyi Biotec plans to establish a Center of Excellence in Hyderabad within four months to begin training personnel. They intend to establish excellence centers across India to cater to the diverse needs of different regions, with plans for further expansion in key cities such as Bangalore, Delhi, and Mumbai.
Currently, Miltenyi Biotec has a relatively small presence in India with 11 employees. However, as they progress, they aim to expand their team, emphasizing the importance of talent acquisition to drive their operations forward. They also leverage strong partnerships to serve customers efficiently, with plans to further expand their workforce as needed to meet growing demand.
